Glipizide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Glipizide: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Glipizide is a second-generation sulfonylurea, clinically established for the management of Type 2 Diabetes Mellitus by stimulating pancreatic beta-cell insulin secretion. The TxGNN model predicts it may be effective for Opsismodysplasia, a rare skeletal dysplasia caused by INPPL1 gene mutations. Currently, 0 clinical trials and 0 publications directly support this repurposing direction, and the biological rationale is weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 Diabetes Mellitus |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 98.77% |
| Evidence Level | L5 |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on established pharmacological knowledge, Glipizide is a second-generation sulfonylurea that acts by blocking ATP-sensitive potassium channels (KATP channels) on pancreatic beta cells, triggering membrane depolarisation and calcium-mediated insulin exocytosis. Its efficacy in lowering blood glucose in Type 2 Diabetes Mellitus is well-proven.
Opsismodysplasia is a rare autosomal recessive skeletal dysplasia caused by loss-of-function mutations in the INPPL1 gene (encoding SHIP2), which encodes an inositol phosphatase involved in PI3K/Akt signalling. There is no established direct mechanistic link between KATP channel blockade and skeletal chondrocyte development or INPPL1 pathway regulation.
The TxGNN prediction likely originates from a distant network association within the phosphorylation signalling pathway subgraph in the knowledge graph, rather than a biologically validated mechanism. Given the fundamental disconnect between Glipizide's mode of action and the pathogenesis of opsismodysplasia, this prediction has very limited biological plausibility and should be treated as a hypothesis-generating signal only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Glipizide is currently not registered in Singapore. No product authorisations on record.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is supported solely by a TxGNN model score with no clinical trials, no human literature, and no credible mechanistic pathway connecting Glipizide's KATP-channel-dependent insulin secretion mechanism to the skeletal phenotype of opsismodysplasia (an INPPL1-driven PI3K/Akt signalling disorder). The prediction likely reflects a distant graph topology association rather than a therapeutically relevant biological relationship.
To proceed, the following would be needed:
- Preclinical evidence (in vitro or animal models) demonstrating any effect of KATP channel modulation or sulphonylureas on INPPL1-deficient chondrocytes or skeletal development
- Mechanistic studies clarifying whether SHIP2/INPPL1 activity is functionally coupled to KATP channel signalling in bone tissue
- MOA data from DrugBank to support a formal mechanistic gap analysis
- Singapore/TFDA package insert review to assess safety and contraindications before any investigational use is considered
- Given that Glipizide is not registered in Singapore, a regulatory pathway assessment would also be required prior to any clinical application
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.